Abstract
Background: JAK/STAT signal pathway, a requisite part in the signaling process of growth factors and cytokines, has become attractive targets for numerous immune, inflammatory and hematopoietic diseases.
Objective: Herein, we present a review of the JAK/STAT signal pathway, the structure, biological function, mechanism of the JAKs and STATs along with a summary of the up-to-date clinical or approved JAK inhibitors which are involved in the treatment of various kinds of tumors and other immunity indications. Moreover, kinds of recently discovered JAKs inhibitors with potent activity or promising selectivity are also briefly discussed.
Conclusion: Research and development of isoform selective JAK inhibitors has become a hot topic in this field. With the assistance of high throughput screening and rational drug design, more and more JAK inhibitors with improved selective profiles will be discovered as biological probes and even therapeutic agents.
Keywords: Inflammation, JAK, STAT, kinase inhibitors, selectivity, signal transduction.
Current Drug Targets
Title:JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
Volume: 19 Issue: 5
Author(s): Qianwen Gao, Xuewu Liang, Abdul Sami Shaikh, Jie Zang, Wenfang Xu*Yingjie Zhang*
Affiliation:
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Wenhua Road, 250012, Jinan, Shandong,China
- Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, 44, West Wenhua Road, 250012, Jinan, Shandong,China
Keywords: Inflammation, JAK, STAT, kinase inhibitors, selectivity, signal transduction.
Abstract: Background: JAK/STAT signal pathway, a requisite part in the signaling process of growth factors and cytokines, has become attractive targets for numerous immune, inflammatory and hematopoietic diseases.
Objective: Herein, we present a review of the JAK/STAT signal pathway, the structure, biological function, mechanism of the JAKs and STATs along with a summary of the up-to-date clinical or approved JAK inhibitors which are involved in the treatment of various kinds of tumors and other immunity indications. Moreover, kinds of recently discovered JAKs inhibitors with potent activity or promising selectivity are also briefly discussed.
Conclusion: Research and development of isoform selective JAK inhibitors has become a hot topic in this field. With the assistance of high throughput screening and rational drug design, more and more JAK inhibitors with improved selective profiles will be discovered as biological probes and even therapeutic agents.
Export Options
About this article
Cite this article as:
Gao Qianwen, Liang Xuewu, Shaikh Sami Abdul, Zang Jie, Xu Wenfang*, Zhang Yingjie*, JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases, Current Drug Targets 2018; 19 (5) . https://dx.doi.org/10.2174/1389450117666161207163054
DOI https://dx.doi.org/10.2174/1389450117666161207163054 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology Effects of Agaricus Blazei Extract Plus Lactoferrin or Lactoferrin Alone on Tumor Growth and UFT-Induced Adverse Reactions in Sarcoma 180- or Highly Metastatic Osteosarcoma LM8-Bearing Mice
The Natural Products Journal Natural Product Origins of Hsp90 Inhibitors
Current Cancer Drug Targets Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Nanocarriers for Photodynamic Therapy Intended to Cutaneous Tumors
Current Drug Targets Antiviral Properties of Quinolone-based Drugs
Current Drug Targets - Infectious Disorders Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets Overcoming the Drug Resistance Problem with Second-Generation Tyrosine Kinase Inhibitors: From Enzymology to Structural Models
Current Medicinal Chemistry Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry HGF and RhoGTPases in Cancer Cell Motility
Current Signal Transduction Therapy Chemokines and Defensins as HIV Suppressive Factors: An Evolving Story
Current Pharmaceutical Design Differential Splicing, Disease and Drug Targets
Infectious Disorders - Drug Targets Physiologically Based Pharmacokinetic Models: Integration of In Silico Approaches with Micro Cell Culture Analogues
Current Drug Metabolism A Feature-Free 30-Disease Pathological Brain Detection System by Linear Regression Classifier
CNS & Neurological Disorders - Drug Targets Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design The Renaissance of the 68Ge/68Ga Radionuclide Generator Initiates New Developments in 68Ga Radiopharmaceutical Chemistry
Current Topics in Medicinal Chemistry Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies
Current Drug Targets